Michael Ostolski
Nurse Practitioner · Lockport, NYNPI 1851355747
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 543 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,120 and has fallen 98.5% since, to $62 in 2024. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 543 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$725
- GSK$709
- Mannkind Corporation$667
- AbbVie$560
- plus $5K from 33 others
What the payments were for
- Food & beverage$9,58997%
- Education$2032%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,462 |
| Novo Nordisk | 66 | $1,040 |
| Lilly USA, LLC | 44 | $725 |
| GSK | 47 | $709 |
| Mannkind Corporation | 29 | $667 |
| AbbVie | 32 | $560 |
| Amgen | 29 | $546 |
| Boehringer Ingelheim | 35 | $544 |
| Pfizer | 29 | $510 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $385 |
| Teva Pharmaceuticals USA, Inc. | 16 | $339 |
| Abbott | 16 | $314 |
| Otsuka America Pharmaceutical, Inc. | 15 | $228 |
| Exact Sciences | 10 | $202 |
| Astellas Pharma US Inc | 7 | $201 |
| Bayer | 9 | $143 |
| Amarin Pharma, Inc. | 7 | $122 |
| Vanda Pharmaceuticals Inc. | 5 | $108 |
| Merck | 5 | $96 |
| Novartis | 6 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Nestle Healthcare Nutrition Inc. | 4 | $76 |
| Biohaven Pharmaceuticals, Inc. | 4 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Johnson & Johnson | 4 | $69 |
| Mylan Specialty L.p. | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Upsher-smith Laboratories LLC | 2 | $44 |
| Insulet Corporation | 2 | $39 |
| Gilead | 1 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Grifols USA, LLC | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$460
- BREZTRI$416
- BEVESPI AEROSPHERE$174
- RYBELSUS$125
How this compares
$9,852 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $23,426 |
| FarxigaDapagliflozin Propanediol | 21 | $15,762 |
| TrulicityDulaglutide | 11 | $11,657 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,076 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,636 |
| Atorvastatin Calcium | 133 | $1,459 |
| Levothyroxine Sodium | 99 | $1,074 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $917 |
| Rosuvastatin Calcium | 47 | $820 |
| Omeprazole | 79 | $780 |
| Gabapentin | 51 | $662 |
| Duloxetine Hcl | 26 | $557 |
| Losartan Potassium | 57 | $469 |
| Metoprolol Succinate | 25 | $460 |
| Montelukast Sodium | 28 | $431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $510 | $23,42628 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,462 | $23,39832 claims |
| Lilly USA, LLCTrulicity | $725 | $11,65711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Lockport
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.